On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

(American Journal of Psychiatry) The FDA is expected to make its hotly anticipated decision on Bristol Myers Squibb's potential first-in-class schizophrenia drug xanomeline-trospium (KarXT ...

and ANSWERS Straight Chicken Formula for Dogs “out of an abundance of caution,” according to the notice posted by the Food and Drug Administration (FDA). The samples that tested positive for ...